BioCentury | Feb 22, 2020
Translation in Brief

Storm's open-access algorithm for RNA epigenetics; plus Duke studies show checkpoint blockers promote anti-HIV bNAbs and reduce opioid efficacy

Algorithm from Storm and academic collaborators for high-throughput analysis of RNA epigenetics  Storm Therapeutics Ltd. and collaborators at the University of Pennsylvania and the University of Tübingen have created a computational algorithm, Nucleic Acid Search...
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new...
BioCentury | Feb 21, 2020
Product Development

Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit

BioMarin's hemophilia gene therapy gets Priority Review  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) could become the first company to have a hemophilia gene therapy approved in the U.S. FDA accepted and granted Priority Review to a BLA...
BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

Spruce Biosciences hopes two rounds of financing will be enough to deliver pivotal data for its lead program, which takes a non-steroidal approach to treating endocrine disorders such as classic congenital adrenal hyperplasia (CAH). Omega...
BioCentury | Feb 20, 2020
Product Development

Insights on COVID-19 vaccine, mAb development from spike protein structure

A UT Austin and NIH Vaccine Research Center team has uncovered the structure of the COVID-19 spike protein, which mediates viral entry into cells via membrane fusion. The findings, published in a Science paper Wednesday,...
BioCentury | Feb 19, 2020
Regulation

Regulatory Roundup: Priority Review for Xpovio, Tecentriq in new indications; plus CRLs delay Keytruda dosing update

FDA granted Priority Review to supplemental applications for Karyopharm's Xpovio and Roche's Tecentriq, setting June deadlines for decisions that could expand each drug's label. The agency will consider granting accelerated approval to Xpovio selinexor to...
BioCentury | Feb 18, 2020
Product Development

Riptide peptide turns TAMs proinflammatory

Riptide has lifted the curtain on its first immuno-oncology program, RP-182, which comprises an engineered peptide that reprograms tumor-associated macrophages to become proinflammatory. Strategies to convert immunosuppressive macrophages into proinflammatory cells have been gaining momentum...
BioCentury | Feb 14, 2020
Product Development

AML’s growing options

For acute myelogenous leukemia patients, 2017 marked the end of a more than 40 year drought in which chemotherapy was the only treatment option. In the last three years, eight new AML therapies have come...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BioCentury | Feb 13, 2020
Finance

Vivo-led $105M round to spur development of ALX’s CD47

Encouraged by safety data for ALX’s CD47-targeted cancer therapy, Vivo Capital led the biotech’s $105 million series C Wednesday to fuel its clinical catch-up to its most advanced competitor. Other new investors including funds managed...
Items per page:
1 - 10 of 32581